Compare IMNM & LIND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMNM | LIND |
|---|---|---|
| Founded | 2006 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Transportation Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.3B |
| IPO Year | 2020 | 2011 |
| Metric | IMNM | LIND |
|---|---|---|
| Price | $17.97 | $34.17 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 17 | 6 |
| Target Price | $35.19 | ★ $36.00 |
| AVG Volume (30 Days) | ★ 1.4M | 851.8K |
| Earning Date | 11-05-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.40 | 5.97 |
| EPS | N/A | ★ 0.07 |
| Revenue | ★ $6,941,000.00 | N/A |
| Revenue This Year | N/A | $13.49 |
| Revenue Next Year | $18,803.97 | $10.22 |
| P/E Ratio | ★ N/A | $504.29 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $14.64 | $11.37 |
| 52 Week High | $30.06 | $36.97 |
| Indicator | IMNM | LIND |
|---|---|---|
| Relative Strength Index (RSI) | 35.71 | 53.53 |
| Support Level | $17.83 | $24.55 |
| Resistance Level | $23.48 | $34.98 |
| Average True Range (ATR) | 0.98 | 1.38 |
| MACD | 0.14 | -0.25 |
| Stochastic Oscillator | 32.67 | 16.57 |
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.
Lindblad Expeditions Holdings Inc provides expedition cruising and adventure travel services. The company operates in two segments: Lindblad and Land Experiences, of which Lindblad generates the vast majority of its revenue. It offers itineraries that feature up-close encounters with wildlife, nature, history, and culture, as well as promote guest empowerment and interactivity. It operates expeditions on intimately-scaled ships and interaction between guests, crew, and the teams of scientists, naturalists, researchers, and photographers that participate in the expeditions. Lindblad operates a fleet of twelve owned expedition ships and five seasonal charter vessels under the Lindblad brand.